

# CITATION REPORT

List of articles citing

**Serum urate levels and gout flares: analysis from managed care data**

**DOI: 10.1097/01.rhu.0000209882.50228.9f**  
**Journal of Clinical Rheumatology, 2006, 12, 61-5.**

**Source:** <https://exaly.com/paper-pdf/40258500/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
149	The economic burden of gout on an employed population. <i>Current Medical Research and Opinion</i> , <b>2006</b> , 22, 1381-9	2.5	59
148	Therapeutic advances in gout. <b>2007</b> , 19, 122-7		30
147	Quality of care for gout in the US needs improvement. <b>2007</b> , 57, 822-9		153
146	Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?. <b>2007</b> , 57, 1324-8		117
145	Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. <i>Clinical Rheumatology</i> , <b>2007</b> , 26, 1459-65	3.9	64
144	Uricase and other novel agents for the management of patients with treatment-failure gout. <b>2007</b> , 9, 258-64		34
143	Gout management: let's get it right this time. <b>2008</b> , 59, 1535-7		11
142	Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. <b>2008</b> , 59, 1540-8		429
141	PEG-uricase in the management of treatment-resistant gout and hyperuricemia. <b>2008</b> , 60, 59-68		208
140	Atherogenic serum lipid profile is an independent predictor for gouty flares in patients with gouty arthropathy. <i>Rheumatology</i> , <b>2009</b> , 48, 262-5	3.9	8
139	Willingness to pay for a cure in patients with chronic gout. <b>2008</b> , 28, 606-13		13
138	Febuxostat, a novel drug for the treatment of hyperuricemia of gout. <b>2008</b> , 3, 421-427		5
137	Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. <i>Annals of the Rheumatic Diseases</i> , <b>2008</b> , 67, 960-6	2.4	348
136	Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. <i>Rheumatology</i> , <b>2009</b> , 48, 188-94	3.9	181
135	We can make gout management more successful now. <b>2008</b> , 20, 167-72		38
134	We can make gout management more successful now. <b>2008</b> , 7, 308-313		
133	Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. <b>2010</b> , 4, 25-36		7

132	Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1032-40	4.1	71
131	Febuxostat treatment for gout: what the clinician needs to know. <b>2009</b> , 1, 67-9		
130	Toward a valid definition of gout flare: results of consensus exercises using Delphi methodology and cognitive mapping. <b>2009</b> , 61, 535-43		35
129	Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1273-82	4.1	197
128	Factors associated with recurrent hospital admissions for gout: a case-control study. <i>Journal of Clinical Rheumatology</i> , <b>2009</b> , 15, 271-4	1.1	28
127	The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. <i>Journal of Clinical Rheumatology</i> , <b>2009</b> , 15, 3-7	1.1	75
126	Gout: new advances in the diagnosis and management of an old disease. <b>2009</b> , 4, 203-220		6
125	Update on emerging urate-lowering therapies. <b>2009</b> , 21, 143-9		37
124	Adherence to treatment guidelines in two primary care populations with gout. <i>Rheumatology International</i> , <b>2010</b> , 30, 749-53	3.6	28
123	The current state of care in gout: Addressing the need for better understanding of an ancient disease. <b>2010</b> , 22 Suppl 1, 623-36		4
122	Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. <b>2010</b> , 70, 57-64		16
121	New advances in the treatment of gout: review of pegloticase. <b>2010</b> , 6, 543-50		30
120	Management of hyperuricemia in gout: focus on febuxostat. <b>2010</b> , 5, 7-18		35
119	Chronic gout: epidemiology, disease progression, treatment and disease burden. <i>Current Medical Research and Opinion</i> , <b>2010</b> , 26, 2813-21	2.5	72
118	The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. <b>2010</b> , 12, R63		338
117	Prevalence of contraindications and prescription of pharmacologic therapies for gout. <b>2011</b> , 124, 155-63		142
116	Gout therapeutics: new drugs for an old disease. <b>2011</b> , 377, 165-77		154
115	The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach. <i>Journal of Clinical Rheumatology</i> , <b>2011</b> , 17, 1-6	1.1	111

114	Impact of deficits in gout care on hospitalizations. <i>Journal of Clinical Rheumatology</i> , <b>2011</b> , 17, 389-91	1.1	8
113	A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout. <i>Journal of Clinical Rheumatology</i> , <b>2011</b> , 17, S11-2	1.1	
112	Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy. <b>2011</b> , 90, 363-4		2
111	Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers. <i>Seminars in Arthritis and Rheumatism</i> , <b>2011</b> , 40, 483-500	5.3	39
110	Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. <b>2011</b> , 12, 103		50
109	Quality of care in patients with gout: why is management suboptimal and what can be done about it?. <b>2011</b> , 13, 154-9		36
108	Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1605-12	4.7	81
107	2011 recommendations for the diagnosis and management of gout and hyperuricemia. <b>2011</b> , 39, 98-123		31
106	Treatment and prophylaxis of gout flare in the clinic: an office-based approach to gout management. <b>2011</b> , 123, 151-65		1
105	Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. <i>Rheumatology</i> , <b>2011</b> , 50, 740-5	3.9	65
104	Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. <i>American Journal of Therapeutics</i> , <b>2012</b> , 19, e157-66	1	43
103	Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. <i>Rheumatology</i> , <b>2012</b> , 51, 2004-12	3.9	41
102	Living with gout in New Zealand: an exploratory study into people's knowledge about the disease and its treatment. <i>Journal of Clinical Rheumatology</i> , <b>2012</b> , 18, 125-9	1.1	27
101	Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. <i>Seminars in Arthritis and Rheumatism</i> , <b>2012</b> , 42, 155-65	5.3	21
100	Riloncept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 1462-70	4.7	81
99	Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. <b>2012</b> , 10, 117		112
98	Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial. <b>2012</b> , 10, 15		1
97	The rheumatology of gout. <b>2012</b> , 19, 404-12		1

96	Safety of urate-lowering therapies: managing the risks to gain the benefits. <b>2012</b> , 38, 663-80		14
95	Developing a provisional definition of flare in patients with established gout. <b>2012</b> , 64, 1508-17		73
94	Evaluation of health care costs and utilization patterns for patients with gout. <b>2012</b> , 34, 640-52		37
93	Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. <b>2012</b> , 64, 876-84		73
92	Economic burden of gouty arthritis attacks for employees with frequent and infrequent attacks. <b>2013</b> , 16, 138-45		19
91	A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. <i>Seminars in Arthritis and Rheumatism</i> , <b>2013</b> , 43, 367-75	5-3	58
90	Proceedings of the 2013 Rheumatology Winter Clinical Symposia. <i>Seminars in Arthritis and Rheumatism</i> , <b>2013</b> , 42, 667-73	5-3	
89	Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. <b>2013</b> , 14, 170		54
88	Gout-related health care utilization in US emergency departments, 2006 through 2008. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 571-7	4-7	36
87	Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. <b>2013</b> , 35, 180-9		37
86	Epidemiology of gout. <b>2013</b> , 6-23		
85	Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. <i>Rheumatology</i> , <b>2013</b> , 52, 1285-92	3-9	68
84	Current concepts in the treatment of gouty arthritis. <b>2013</b> , 5, 6-12		12
83	The impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout. <b>2014</b> , 16, R132		41
82	Remembering the forgotten non-communicable diseases. <b>2014</b> , 12, 200		51
81	Treatment of acute gout: a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 44, 31-8	5-3	56
80	The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. <b>2014</b> , 15, 26		52
79	Long-term management of gout: nonpharmacologic and pharmacologic therapies. <b>2014</b> , 40, 357-74		17

78	Evaluating appropriate use of prophylactic colchicine for gout flare prevention. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1258-62	4.7	3
77	Riloncept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1703-11	4.1	41
76	Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 177-82	2.4	121
75	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 328-35	2.4	182
74	Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study. <b>2014</b> , 16, R82		47
73	Using natural language processing and machine learning to identify gout flares from electronic clinical notes. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1740-8	4.7	27
72	A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. <i>International Journal of Rheumatic Diseases</i> , <b>2015</b> , 18, 669-78	2.3	23
71	A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database. <i>Journal of Clinical Rheumatology</i> , <b>2015</b> , 21, 411-8	1.1	9
70	How neutrophil extracellular traps orchestrate the local immune response in gout. <b>2015</b> , 93, 727-34		39
69	Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. <b>2015</b> , 17, 120		43
68	Measuring physician adherence with gout quality indicators: a role for natural language processing. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 273-9	4.7	8
67	Patient and clinical characteristics associated with gout flares in an integrated healthcare system. <i>Rheumatology International</i> , <b>2015</b> , 35, 1799-807	3.6	18
66	Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative. <i>International Journal of Rheumatic Diseases</i> , <b>2015</b> , 18, 341-51	2.3	35
65	An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1702-7	4.1	62
64	Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 504-12	4.1	50
63	Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease. <b>2016</b> , 22, 326-36		8
62	Validation of claims-based algorithms for gout flares. <b>2016</b> , 25, 820-6		12
61	Gout Prophylaxis Evaluated According to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 924-30	4.1	5

60	Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?. <b>2016</b> , 128, 706-15		27
59	Prevalence of comorbidities and management of gout in a tropical city in Australia. <i>Rheumatology International</i> , <b>2016</b> , 36, 1753-1758	3.6	4
58	[Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)]. <b>2016</b> , 75 Suppl 2, 11-60		20
57	Management of gout in the real world: current practice versus guideline recommendations. <b>2016</b> , 128, 106-14		7
56	[Hyperuricemia. When and how to treat?]. <b>2016</b> , 57, 194-201		6
55	Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 388-396	4.1	74
54	Gout Self-Management in African American Veterans: A Qualitative Exploration of Challenges and Solutions From Patients' Perspectives. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1724-1732	4.7	9
53	Lesinurad combination therapy with allopurinol in gout: do CLEAR studies make the treatment of gout clearer?. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 779-781	2.4	2
52	Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 497-503	2.3	5
51	Serum apoprotein A1 levels are inversely associated with disease activity in gout: From a southern Chinese Han population. <b>2017</b> , 96, e6780		1
50	Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. <b>2017</b> , 35, 1073-1085		6
49	A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1522-1528	2.4	77
48	Editorial: Do Not Let Gout Apathy Lead to Gouty Arthropathy. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 479-482		12
47	Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 2065-2070	2.4	43
46	Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients. <i>Rheumatology International</i> , <b>2017</b> , 37, 1435-1440	3.6	10
45	Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 649-656	3.9	30
44	The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 46, 594-600	5.3	48
43	Serum uric acid levels and the risk of flares among gout patients in a US managed care setting. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 117-124	2.5	14

42	Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout. <i>Annals of Pharmacotherapy</i> , <b>2017</b> , 51, 301-306	2.9	8
41	Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. <i>ClinicoEconomics and Outcomes Research</i> , <b>2017</b> , 9, 629-639	1.7	9
40	Urate-Lowering Therapy. <b>2017</b> , 1061-1074.e3		2
39	Development of the American College of Rheumatology Electronic Clinical Quality Measures for Gout. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 659-671	4.7	13
38	Brief Report: Validation of a Definition of Flare in Patients With Established Gout. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 462-467	9.5	41
37	How Would You Manage This Patient With Gout?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, 788-795	8	
36	Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model. <i>Value in Health</i> , <b>2018</b> , 21, 1373-1381	3.3	8
35	Gicht. <i>Rheuma Plus</i> , <b>2019</b> , 18, 43-45	0	
34	Incident gout and chronic Kidney Disease: healthcare utilization and survival. <i>BMC Rheumatology</i> , <b>2019</b> , 3, 11	2.9	5
33	Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 2233-2239	3.9	3
32	Changes in the Presentation of Incident Gout and the Risk of Subsequent Flares: A Population-based Study over 20 Years. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 613-618	4.1	8
31	Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 449-460	4.1	4
30	Development and Pilot Testing of MyGoutCare: A Novel Web-Based Platform to Educate Patients With Gout. <i>Journal of Clinical Rheumatology</i> , <b>2020</b> , 26, 320-326	1.1	2
29	UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis. <i>Joint Bone Spine</i> , <b>2020</b> , 87, 647-651	2.9	4
28	Prophylaxis of Acute Arthritis at Initiation of Urate-Lowering Therapy in Gout Patients. <b>2020</b> ,		3
27	Which factors predict discordance between a patient and physician on a gout flare?. <i>Rheumatology</i> , <b>2021</b> , 60, 773-779	3.9	2
26	Utilization of acute gout prophylaxis in the real world: a retrospective database cohort analysis. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 1017-1026	3.9	4
25	Comparison of the efficacy and safety of various anti-inflammatory drugs in urate-lowering therapy initiation in patients with gout (preliminary data). <i>Sovremennaya Revmatologiya</i> , <b>2021</b> , 15, 50-56	0.7	3



24	Contentious Issues in Gout Management: The Story so Far. <i>Open Access Rheumatology: Research and Reviews</i> , <b>2021</b> , 13, 111-122	2.4	2
23	Quality of care in people requiring hospital admission for gout in Aotearoa New Zealand: a nationwide analysis. <i>Internal Medicine Journal</i> , <b>2021</b> ,	1.6	
22	Incorporating gout guideline advice into urate reports is associated with reduced hospital admissions: results of an observational study. <i>Rheumatology</i> , <b>2021</b> ,	3.9	
21	Etiology and pathogenesis of gout. <b>2011</b> , 1841-1857.e3		2
20	Current and future therapeutic options for the management of gout. <i>American Journal of Therapeutics</i> , <b>2010</b> , 17, 402-17	1	9
19	Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0146172	3.7	14
18	Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout. <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2019</b> , 56, 760-766	0.9	6
17	Adherence to urate-lowering therapy while following the national guidelines for the management of patients with gout (preliminary evidence). <i>Sovremennaya Revmatologiya</i> , <b>2020</b> , 14, 70-75	0.7	4
16	[Time course of changes in the clinical manifestations of gout in men: data of a 7-year retrospective follow-up]. <i>Terapevticheskii Arkhiv</i> , <b>2015</b> , 87, 10-15	0.9	13
15	M90 Arthritis. <b>2010</b> , 1-42		
14	NHG-Standaard Arthritis. <b>2011</b> , 579-601		
13	Antihyperuricemic Agents. <b>2013</b> , 1001-1013		
12	Etiology and pathogenesis of gout. <b>2015</b> , 1555-1568		
11	Gelenk- und Muskelschmerzen. <i>Springer Reference Medizin</i> , <b>2019</b> , 1-27	0	
10	Gelenk- und Muskelschmerzen. <i>Springer Reference Medizin</i> , <b>2019</b> , 347-373	0	
9	RhazesRprescriptions in treatment of gout. <i>Iranian Red Crescent Medical Journal</i> , <b>2012</b> , 14, 108-12	1.3	3
8	Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor. <i>American Health and Drug Benefits</i> , <b>2017</b> , 10, 393-401	1.7	28
7	The Role of Advanced Imaging in Gout Management.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 811323	8.4	1

- |   |   |     |   |
|---|---|-----|---|
| 6 | Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0261940                            | 3-7 |   |
| 5 | 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout.. <i>International Journal of Rheumatic Diseases</i> , <b>2022</b> , 25, 7-20                           | 2-3 | 2 |
| 4 | Management of gout following 2016/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom. <i>Lancet Regional Health - Europe, The</i> , <b>2022</b> , 100416 |     | ○ |
| 3 | Ultrasonography in the prediction of gout flares: a 12-month prospective observational study.   |     | ○ |
| 2 | Towards a more ambitious uricemia target to improve joint and cardiovascular outcomes in gout. 20-25  |     | ○ |
| 1 | Evaluation of the effect of long-term use of glucocorticoids on the risk of developing diabetes mellitus in patients with gout. <b>2023</b> , 19, 378-386   |     | ○ |